Ethiopia

Population 2018 109 million

<table>
<thead>
<tr>
<th>Estimates of TB burden*, 2018</th>
<th>Number (thousands)</th>
<th>Rate (per 100 000 population)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total TB incidence</td>
<td>165 (116–223)</td>
<td>151 (107–204)</td>
</tr>
<tr>
<td>HIV-positive TB incidence</td>
<td>7.6 (5.3–10)</td>
<td>7 (4.9–9.4)</td>
</tr>
<tr>
<td>MDR/RR-TB incidence**</td>
<td>1.6 (1–2.2)</td>
<td>1.4 (0.96–2)</td>
</tr>
<tr>
<td>HIV-negative TB mortality</td>
<td>24 (15–36)</td>
<td>22 (14–33)</td>
</tr>
<tr>
<td>HIV-positive TB mortality</td>
<td>2.2 (1.5–3)</td>
<td>2 (1.4–2.8)</td>
</tr>
</tbody>
</table>

Estimated proportion of TB cases with MDR/RR-TB, 2018
New cases 0.71% (0.62–0.8)
Previously treated cases 16% (14–17)

TB case notifications, 2018
Total new and relapse 113,613
- % tested with rapid diagnostics at time of diagnosis
  - % with known HIV status 92%
  - % pulmonary 69%
  - % bacteriologically confirmed*** 62%
  - % children aged 0-14 years 10%
  - % women 40%
  - % men 50%
Total cases notified 114,233

Universal health coverage and social protection
TB treatment coverage (notified/estimated incidence), 2018 69% (51–98)
TB patients facing catastrophic total costs
TB case fatality ratio (estimated mortality/estimated incidence), 2018 17% (9–25)

TB/HIV care in new and relapse TB patients, 2018
Patients with known HIV status who are HIV-positive 4,816 5%
  - on antiretroviral therapy 4,393 91%

Drug-resistant TB care, 2018
% of bacteriologically confirmed TB cases tested for rifampicin resistance***
  - New cases 80%
  - Previously treated cases 100%
Laboratory-confirmed cases*
Patients started on treatment**
MDR/RR-TB cases tested for resistance to second-line drugs 360

Treatment success rate and cohort size
Success Cohort
New cases registered in 2017 96% 113,690
Previously treated cases registered in 2017
MDR/RR-TB cases started on second-line treatment in 2016 72% 703
XDR-TB cases started on second-line treatment in 2016

TB preventive treatment, 2018
% of HIV-positive people (newly enrolled in care) on preventive treatment 49%
% of children (aged < 5) household contacts of bacteriologically-confirmed 22% (20–24)
TB cases on preventive treatment

TB financing, 2019
National TB budget (US$ millions) 94
Funding source: 11% domestic, 29% international, 60% unfunded

* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Calculated for pulmonary cases only
* Includes cases with unknown previous TB treatment history
** Includes patients diagnosed before 2018 and patients who were not laboratory-confirmed

Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
Generated: 2020-03-20 Data: www.who.int/tb/data